Cargando…

A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia

BACKGROUND: Pomaglumetad methionil (LY2140023 monohydrate) is a potent and highly selective agonist for the metabotropic glutamate mGluR2 and mGluR3 receptors. We present results of a pivotal clinical study H8Y-MC-HBBM assessing the efficacy of LY2140023 in improving symptoms as a monotherapy in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Downing, AnnCatherine M, Kinon, Bruce J, Millen, Brian A, Zhang, Lu, Liu, Lin, Morozova, Margarita A, Brenner, Ronald, Rayle, Tami Jo, Nisenbaum, Laura, Zhao, Fangyi, Gomez, Juan Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276262/ https://www.ncbi.nlm.nih.gov/pubmed/25539791 http://dx.doi.org/10.1186/s12888-014-0351-3

Ejemplares similares

Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
por: Adams, David H., et al.
Publicado: (2014)

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
por: Adams, David H, et al.
Publicado: (2013)

Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia
por: Nisenbaum, Laura K., et al.
Publicado: (2016)

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
por: Yingling, Jonathan M., et al.
Publicado: (2017)

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)
por: Kinon, Bruce J.
Publicado: (2019)

Effects of creatine monohydrate supplementation on exercise-induced apoptosis in athletes: A randomized, double-blind, and placebo-controlled study
por: Rahimi, Rahman, et al.
Publicado: (2015)

Treatment with Creatine Monohydrate in Spinal and Bulbar Muscular Atrophy: Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial
por: Hijikata, Yasuhiro, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression
por: Toniolo, Ricardo Alexandre, et al.
Publicado: (2017)

EHMTI-0178. CGRP monoclonal antibody LY2951742 for the prevention of migraine: a phase 2, randomized, double-blind, placebo-controlled study
por: Goadsby, P, et al.
Publicado: (2014)

Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study
por: Gu, Jiemei, et al.
Publicado: (2022)

Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts
por: Maier, Armin, et al.
Publicado: (2015)

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
por: Herbertz, Stephan, et al.
Publicado: (2015)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
por: Zhang, Qing, et al.
Publicado: (2018)

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome
por: Luo, Linlin, et al.
Publicado: (2016)

A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
por: Shiina, Akihiro, et al.
Publicado: (2010)

A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps
por: Barna, Olha, et al.
Publicado: (2021)

A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder
por: Mi, Weifeng, et al.
Publicado: (2023)

Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study
por: Kovacs, Richard J., et al.
Publicado: (2014)

Developmental and communicative interrelations of Ly123 and Ly1 cell sets
Publicado: (1980)

Neces-SARI-ly?
por: Martin-Loeches, Ignacio, et al.
Publicado: (2016)

Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial
por: Barnes, Thomas R.E., et al.
Publicado: (2018)

A Short-Term, Multicenter, Placebo-Controlled, Randomized Withdrawal Study of a Metabotropic Glutamate 2/3 Receptor Agonist Using an Electronic Patient-Reported Outcome Device in Patients With Schizophrenia
por: Stauffer, Virginia L., et al.
Publicado: (2014)

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
por: Brown, David, et al.
Publicado: (2019)

Efficacy and Safety of LY3127804, an Anti-Angiopoietin-2 Antibody, in a Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients Hospitalized with Pneumonia and Presumed or Confirmed COVID-19
por: Jones, Rosie S., et al.
Publicado: (2022)

Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
por: Zhu, Weiwei, et al.
Publicado: (2014)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study
por: Veerman, S. R. T., et al.
Publicado: (2016)

Acetaminophen as Adjuvant to Risperidone in Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
por: Arabzadeh, Somaye, et al.
Publicado: (2018)

Running Mad-ly into mitosis
por: LeBrasseur, Nicole
Publicado: (2004)

Virulence profile: Hinh Ly
por: Ly, Hinh
Publicado: (2016)

Comparison of Mouse Ly5(a) and Ly5(b) Leucocyte Common Antigen Alleles
por: Zebedee, Suzanne L., et al.
Publicado: (1991)

Secretion of Ia antigens by a subpopulation of T cells which are Ly-1+, Ly-2-, and Ia-
Publicado: (1976)

Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial
por: Mi, Weifeng, et al.
Publicado: (2021)

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Sweeney, Christopher J., et al.
Publicado: (2022)

Expression of Ly 1, Ly 2, Thy 1, and TL differentiation antigens on mouse T-cell tumors
Publicado: (1978)

Occurrences and Functions of Ly6C(hi) and Ly6C(lo) Macrophages in Health and Disease
por: Li, Yuan-hui, et al.
Publicado: (2022)

Effects of Withania somnifera in patients of schizophrenia: A randomized, double blind, placebo controlled pilot trial study
por: Agnihotri, Akshay P., et al.
Publicado: (2013)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
por: Takahashi, Nagahide, et al.
Publicado: (2013)

Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
por: Miyaoka, Tsuyoshi, et al.
Publicado: (2015)

Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial
por: Abdallah, Mahmoud S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0s13rpj78m6imvcoh9fp2c8nfm